02754nam 2200685 a 450 991097420770332120251017110110.097866129759129780309186483030918648X9781282975910128297591997803091488490309148847(CKB)2550000000032080(SSID)ssj0000467759(PQKBManifestationID)11320034(PQKBTitleCode)TC0000467759(PQKBWorkID)10490553(PQKB)10059879(MiAaPQ)EBC3378727(Au-PeEL)EBL3378727(CaPaEBR)ebr10443269(CaONFJC)MIL297591(OCoLC)709768285(Perlego)4739345(DNLM)1555848(EXLCZ)99255000000003208020110215d2010 uy 0engurcn|||||||||txtccrCNS clinical trials suicidality and data collection : workshop summary /Sarah Hanson, Miriam Davis, and Bruce Altevogt ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy1st ed.Washington, D.C. National Academies Press2010xii, 75 pBibliographic Level Mode of Issuance: Monograph9780309148832 0309148839 Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration."The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description.SuicideRisk factorsSuicidePreventionSuicideRisk factors.SuicidePrevention.616.85/8445Hanson Sarah1803029Davis Miriam856948Altevogt Bruce M1791694Institute of Medicine (U.S.).Forum on Neuroscience and Nervous System Disorders.National Academies Press (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910974207703321CNS clinical trials4359713UNINA